<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-123219</identifier>
<setSpec>0300-8932</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Safety and Efficacy of Different Paclitaxel-eluting Balloons in a Porcine Model</dc:title>
<dc:description xml:lang="en">Introduction and objectives Paclitaxel-eluting balloons have shown high antiproliferative efficacy in the treatment and prevention of restenosis. Nevertheless, not all available devices are equally effective, which makes it interesting to compare results in a preclinical model. Our objective was to assess the preclinical efficacy and safety of different devices. Methods We implanted 51 metallic stents (Architect®, iVascular) in 17 domestic swine (mean, 25 [3] kg), inserting 1 stent per major coronary artery. Stent postdilatation was performed with different control balloons (n = 10) or paclitaxel-eluting balloons: paclitaxel-eluting balloon 1 (iVascular) (n = 15); paclitaxel-eluting balloon 2 (iVascular) (n = 16) and In.Pact Falcon®(Medtronic) (n = 10). The restenosis rate (using angiography and histomorphometry) and vascular healing parameters (balloon-related vascular injury score, endothelialization rate, and fibrin and inflammation scores) were analyzed at 28 days. Results The distinct paclitaxel-eluting balloons showed a similar degree of stenosis at follow-up, which was significantly lower than that in the control group: diameter stenosis was 9% (12%) vs 34% (18%) by angiography (P &lt; .0001) and was 22% (8%) vs 51% (18%) by histomorphometry (P &lt; .0001). Scores for vascular injury (mean, 0.6 [0.5]) and inflammation (mean, 0.8 [0.3]) were uniformly low across all groups. Drug effect markers differed significantly between the paclitaxel-eluting balloons and control groups, with lower endothelialization rates (87% [10%] vs 99% [2%]; P = .0007) and higher fibrin scores (2.1 [0.7] vs 0.4 [0.5]; P &lt; .0001) in the paclitaxel-eluting (..) (AU)</dc:description>
<dc:creator>Cuellas Ramón, Carlos</dc:creator>
<dc:creator>Regueiro Purriños, Marta</dc:creator>
<dc:creator>Gómez Castel, Alex</dc:creator>
<dc:creator>Pérez-Martínez, Claudia</dc:creator>
<dc:creator>Gonzalo-Orden, José M</dc:creator>
<dc:creator>Pérez de Prado, Armando</dc:creator>
<dc:creator>Fernández-Vázquez, Felipe</dc:creator>
<dc:creator>Molina Crisol, María</dc:creator>
<dc:creator>Duocastella Codina, Luis</dc:creator>
<dc:creator>Diego Nieto, Alejandro</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Introducción y objetivos Los balones liberadores de paclitaxel tienen demostrada eficacia en el tratamiento y la prevención de la restenosis. Sin embargo, no todos los dispositivos comercializados son igualmente efectivos; por ello es importante comparar los resultados en un modelo preclínico. Nuestro objetivo es analizar la seguridad y la eficacia preclínicas de distintos dispositivos. Métodos En 17 cerdos domésticos (25 ± 3 kg) se implantaron 51 stents metálicos (Architect®, iVascular), uno en cada rama coronaria principal, y se sobredilataron con distintos balones de control (n = 10) o liberadores de paclitaxel: balón liberador de paclitaxel 1 (iVascular) (n = 15); balón liberador de paclitaxel 2 (iVascular) (n = 16) e In. Pact Falcon® (Medtronic) (n = 10). Tras 28 días, se analizaron los resultados de restenosis (angiografía e histomorfometría) y de reparación vascular: daño vascular, endotelización, persistencia de fibrina e inflamación. Resultados Los distintos balones liberadores de paclitaxel mostraron valores similares de estenosis en el seguimiento significativamente menores que los controles: angiografía, el 9 ± 12% frente al 34 ± 18% (p &lt; 0,0001); histomorfometría, el 22 ± 8% frente al 51 ± 18% (p &lt; 0,0001). Los grados de daño vascular (0,6 ± 0,5) e inflamación (0,8 ± 0,3) fueron bajos, sin diferencias  (..) (AU)</dc:description>
<dc:source>Rev Esp Cardiol;67(6): 456-462, jun. 2014. ilus, tab</dc:source>
<dc:identifier>ibc-123219</dc:identifier>
<dc:title xml:lang="es">Análisis de la eficacia y la seguridad de distintos balones liberadores de paclitaxel en un modelo animal</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d54857</dc:subject>
<dc:subject>^d841</dc:subject>
<dc:subject>^d4255</dc:subject>
<dc:subject>^d23771^s22045</dc:subject>
<dc:subject>^d52881^s22074</dc:subject>
<dc:subject>^d13933</dc:subject>
<dc:subject>^d30485^s22079</dc:subject>
<dc:subject>^d36021^s22057</dc:subject>
<dc:type>article</dc:type>
<dc:date>201406</dc:date>
</metadata>
</record>
</ibecs-document>
